Clinical characteristics of patients used for genetic and clinical analysis
| Characteristic . | Genetic analysis value . | Clinical analysis value . |
|---|---|---|
| Total patient number | 105 | 82 |
| Female, % | 54.3 | 56.1 |
| Male, % | 45.7 | 43.9 |
| Age (median) | 58 | 58.5 |
| Age range | 22-87 | 28-87 |
| Stage, % | ||
| I | 19.0 | 15.9 |
| II | 5.7 | 7.3 |
| III | 27.6 | 28.1 |
| IV | 44.8 | 48.8 |
| NA: no information | 2.9 | — |
| FLIPI score, % | ||
| Low | 36.2 | 36.6 |
| Intermediate | 35.2 | 41.5 |
| High | 20.0 | 22.0 |
| NA: no information or tNHL | 8.6 | — |
| m7 FLIPI score, % | ||
| Low | 75.2 | 87.7 |
| High | 11.4 | 12.4 |
| NA: no information or tNHL | 13.3 | — |
| Lymphoma type, % | ||
| FL | 91.4 | — |
| Transformed lymphoma (tNHL) | 6.7 | — |
| NA: no information | 1.9 | — |
| Sequenced biopsy, % | ||
| Treatment-naive FL | 80.0 | 100.0 |
| Treated FL* | 11.4 | — |
| Transformed lymphoma (tNHL) | 6.7 | — |
| NA: no information | 1.9 | — |
| Treatment, % | ||
| Rituximab containing regimen | — | 50.0 |
| Other treatment† | — | 22.0 |
| Observation | — | 28.1 |
| Best response to treatment, %‡ | ||
| Complete remission | — | 66.1 |
| Partial remission | — | 28.8 |
| Stable disease | — | 1.7 |
| Progressive disease | — | 3.4 |
| Characteristic . | Genetic analysis value . | Clinical analysis value . |
|---|---|---|
| Total patient number | 105 | 82 |
| Female, % | 54.3 | 56.1 |
| Male, % | 45.7 | 43.9 |
| Age (median) | 58 | 58.5 |
| Age range | 22-87 | 28-87 |
| Stage, % | ||
| I | 19.0 | 15.9 |
| II | 5.7 | 7.3 |
| III | 27.6 | 28.1 |
| IV | 44.8 | 48.8 |
| NA: no information | 2.9 | — |
| FLIPI score, % | ||
| Low | 36.2 | 36.6 |
| Intermediate | 35.2 | 41.5 |
| High | 20.0 | 22.0 |
| NA: no information or tNHL | 8.6 | — |
| m7 FLIPI score, % | ||
| Low | 75.2 | 87.7 |
| High | 11.4 | 12.4 |
| NA: no information or tNHL | 13.3 | — |
| Lymphoma type, % | ||
| FL | 91.4 | — |
| Transformed lymphoma (tNHL) | 6.7 | — |
| NA: no information | 1.9 | — |
| Sequenced biopsy, % | ||
| Treatment-naive FL | 80.0 | 100.0 |
| Treated FL* | 11.4 | — |
| Transformed lymphoma (tNHL) | 6.7 | — |
| NA: no information | 1.9 | — |
| Treatment, % | ||
| Rituximab containing regimen | — | 50.0 |
| Other treatment† | — | 22.0 |
| Observation | — | 28.1 |
| Best response to treatment, %‡ | ||
| Complete remission | — | 66.1 |
| Partial remission | — | 28.8 |
| Stable disease | — | 1.7 |
| Progressive disease | — | 3.4 |
One patient with both treatment-naive and treated biopsies was only counted as treatment-naive.
Other treatment includes: CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, prednisolone), bendamustine-ofatumumab + ofatumumab, XRT (radiation therapy), bendamustine + ofatumumab, cyclophosphamide, CVP (cyclophosphamide, vincristine, prednisolone), CVP + genitope protocol vaccine, and CHOP + XRT.
This excludes patients who were observed.